Latest news
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership - Stock TitanStock Titan · Fri, 07 Aug 2026 15:13:34 GMTViridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:41:01 GMTViridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMTViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Business WireBusiness Wire · Thu, 06 Aug 2026 11:01:00 GMTHow Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors - SahmSahm · Fri, 31 Jul 2026 21:35:59 GMTViridian Therapeutics Inc (1S1.DU) stock price, news, quote and history - uk.finance.yahoo.comuk.finance.yahoo.com · Thu, 30 Jul 2026 14:48:37 GMTGraves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight - PR Newswire UKPR Newswire UK · Wed, 29 Jul 2026 14:31:00 GMT